MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mineralys Therapeutics Inc (MLYS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive momentum and hedge fund interest, the lack of recent news, weak financial performance, and no strong proprietary trading signals suggest holding off on immediate investment.
The MACD is positively expanding (0.612), indicating bullish momentum. RSI at 79.718 is in the neutral zone, showing no overbought or oversold conditions. The stock is trading near its resistance level (R1: 30.629), which could act as a barrier to further price increases. Moving averages are converging, suggesting indecision in the market.
Hedge funds are significantly increasing their positions, with a 516.79% rise in buying activity over the last quarter. Analysts from BofA raised the price target to $51, citing underappreciated peak sales potential for the lead drug lorundrostat.
No recent news or congress trading data to provide additional support for the stock.
In Q4 2025, revenue remained at 0 with no YoY growth. Net income dropped to -$32.23 million (-34.14% YoY), and EPS fell to -0.4 (-59.18% YoY). Gross margin remains at 0, indicating no profitability.
BofA maintains a Buy rating and raised the price target from $46 to $51, citing underappreciated sales potential for lorundrostat. This reflects optimism among analysts but is not supported by strong financials or immediate catalysts.
